cisatracurium

(redirected from Cisatracurium besylate)

cisatracurium

 [sis″at-rah-kūr´e-um]
a nondepolarizing neuromuscular blocking agent administered intravenously as the besylate salt administered intravenously to facilitate endotracheal intubation and to induce skeletal muscle relaxation, either as an adjunct to general anesthesia during surgery or during mechanical ventilation.

cisatracurium

/cis·at·ra·cu·ri·um/ (sis″at-rah-kūr´e-um) a nondepolarizing neuromuscular blocking agent administered intravenously as the besylate salt as an adjunct to general anesthesia or during mechanical ventilation.

cisatracurium

a nondepolarizing neuromuscular blocker.
indications It is used to facilitate endotracheal intubation and skeletal muscle relaxation during mechanical ventilation, surgery, or general anesthesia.
contraindications Known hypersensitivity to this drug prohibits its use.
adverse effects Life-threatening effects include prolonged apnea, bronchospasm, cyanosis, and respiratory depression. Other serious adverse effects include bradycardia, tachycardia, and increased/decreased blood pressure.

cisatracurium

Anesthesiology A stereoisomer of atracurium, a nondepolarizing muscle relaxing anesthetic preferred in multiorgan failure. See Muscle relaxant, Nondepolarizing agent. Cf Depolarizing agent.
References in periodicals archive ?
The increase is due to increased manufacturing, marketing and general activity with the push to gain market share for the Cisatracurium Besylate product.
In the neurological population it is most often used for patients placed on a neuromuscular blockade drip such as cisatracurium besylate (Nimbex), which is accompanied by sedation such as propofol (Diprivan), and for patients placed in a pentobarbital-induced coma.
Tracheal intubation was facilitated with administration of cisatracurium besylate.
Sinobiopharma" or, the "Company") (BULLETIN BOARD: SNBP) is pleased to announce today that it has received approval and authentication from the Trademark Bureau of China for its pre-surgical skeletal muscle relaxant Cisatracurium Besylate, marketed as Kutai, and its newly launched formulation of the anti-hypertension drug Perindopril, marketed as Yitai.
Sales, Production and Marketing Highlights: -- Sales of Cisatracurium Besylate increased by more than 200 percent from 2007 to 2008.
BULLETIN BOARD: SNBP) ("Sinobiopharma" or, the "Company") is pleased to announce that production of its flagship drug, Cisatracurium Besylate, increased by 350% in the first quarter of 2009 compared to production in the first quarter of 2008.
Sinobiopharma distributes Cisatracurium Besylate in 30 provinces and key major cities throughout China through sales partners and other sales networks.
Czesc 1 Ceftazidime 0,25 g, Cisatracurium besylate 10 mg/5 ml i 5 mg/2,5 ml, Mivacurium 10 mg/5 ml i 20 mg/10 ml, Czesc 2 Poractant Alfa 120 mg/1,5 ml, Czesc 3 Lamivudine syrop 10 mg/ml 240 ml ,Lamivudine tabl.
At the same time, as volume has increased, cost of manufacturing Cisatracurium Besylate has decreased to 30% of its price for the nine months ended February 28, 2009, from 64% of its price for the nine months ended February 29, 2008.
5 million units for its flagship product, a patented formulation of Cisatracurium Besylate that is China's top-selling pre-surgical skeletal muscle relaxant.
BULLETIN BOARD: SNBP) is pleased to announce that its patented version of Cisatracurium besylate, a pre-surgical skeletal muscle relaxant marketed as Kutai in China, has successfully concluded its Phase IV Clinical Study.